Evidence map›Paper›PMID 29541888›Full record

ArticleInflammation2018

Nobiletin-Ameliorated Lipopolysaccharide-Induced Inflammation in Acute Lung Injury by Suppression of NF-κB Pathway In Vivo and Vitro.

Weifeng Li, Ruoqi Zhao, Xiumei Wang, Fang Liu, Jinmeng Zhao, Qing Yao, Wenbing Zhi, Zehong He, Xiaofeng Niu

Abstract read
PubMed Publisher
In one paragraph

Article in Inflammation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
8.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 60 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Frontiers in immunology · 2023
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Weifeng LiSchool of Pharmacy, Xi'an Jiaotong University, No. 76 Western Yanta Road, Xi'an City, 710061, Shaanxi Province, People's Republic of China.
Ruoqi ZhaoQueen Mary College, Nanchang University, Nanchang, 330019, People's Republic of China.
Xiumei WangSchool of Pharmacy, Xi'an Jiaotong University, No. 76 Western Yanta Road, Xi'an City, 710061, Shaanxi Province, People's Republic of China.
Fang LiuSchool of Pharmacy, Xi'an Jiaotong University, No. 76 Western Yanta Road, Xi'an City, 710061, Shaanxi Province, People's Republic of China.
Jinmeng ZhaoSchool of Pharmacy, Xi'an Jiaotong University, No. 76 Western Yanta Road, Xi'an City, 710061, Shaanxi Province, People's Republic of China.
Qing YaoSchool of Pharmacy, Xi'an Jiaotong University, No. 76 Western Yanta Road, Xi'an City, 710061, Shaanxi Province, People's Republic of China.
Wenbing ZhiSchool of Pharmacy, Xi'an Jiaotong University, No. 76 Western Yanta Road, Xi'an City, 710061, Shaanxi Province, People's Republic of China.
Zehong HeSchool of Pharmacy, Xi'an Jiaotong University, No. 76 Western Yanta Road, Xi'an City, 710061, Shaanxi Province, People's Republic of China.
Xiaofeng NiuSchool of Pharmacy, Xi'an Jiaotong University, No. 76 Western Yanta Road, Xi'an City, 710061, Shaanxi Province, People's Republic of China. niuxf@mail.xjtu.edu.cn.
Xi'an Jiaotong University · CNNanchang University · CN

Funding

Natural Science Foundation of International Cooperation Projects (Shaanxi Province, PR China) 2013KW26-02
6 · The paper itself

Abstract

Nobiletin (NOB), a citrus polymethoxy flavonoid, has been reported to exhibit anti-inflammatory, anti-cancer, and anti-insulin resistance activities. Although the anti-inflammatory activity of NOB already reported, its involvement in lung protection has not been reported. Thus, this study aimed to investigate the anti-inflammatory response of NOB in lipopolysaccharide (LPS)-stimulated A549 cells and LPS-induced acute lung injury (ALI) in mice. The animals were pre-treated with NOB (5, 10, and 20 mg/kg) or DEX (5 mg/kg) at 12 and 1 h before intranasal instillation of LPS. The severity of pulmonary injury was evaluated 6 h after LPS administration. Results suggested that treatment with NOB dramatically attenuated lung histopathological changes, wet-to-dry (W/D) ratio, myeloperoxidase (MPO) activity, the numbers of inflammatory cells, and TNF-α, IL-6, and NO in BALF induced by LPS. Furthermore, NOB also significantly inhibited the expression of iNOS and the phosphorylation of NF-κBp65 and IκBα. In vitro, NOB inhibited NF-κB activation and TNF-α, IL-6 production in LPS-stimulated A549 cells. Taken together, these results indicated that NOB exhibited a protective effect on ALI, and the possible mechanism is involved in inhibiting NF-κB activation, subsequently inhibiting LPS-induced inflammatory response.

Indexed as

A549 CellsAcute Lung InjuryAnimalsAntioxidantsFlavonesHumansInflammationInterleukin-6LipopolysaccharidesMiceNF-kappa BProtective AgentsTumor Necrosis Factor-alphaAntioxidantsFlavonesIL6 protein, humanInterleukin-6LipopolysaccharidesNF-kappa BnobiletinProtective AgentsTumor Necrosis Factor-alphaacute lung injuryinflammationLPSNF-κBnobiletin

Identifiers

PMID29541888
OpenAlexW2793682834

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.